Targeting the co-inhibitory pathways of T cells, termed T cell checkpoints,12 elicits an antitumor response by shifting the balance from T cell inhibition by co-inhibitory molecules, like LAG-3, PD-1, TIM-3, and CTLA-4, to enhanced pro-inflammatory conditions that no longer support tumor growth.13 The gene discussed is LAG3; the disease is neoplasm.